Video

Edward Fox from the MS Clinic of Central Texas: Alemtuzumab's Long-Term Studies Show Efficacy for Multiple Sclerosis Treatment

Author(s):

With a unique delivery method alemtuzumab, also known as Lemtrada has proven to be an effective treatment option for multiple sclerosis. While careful monitoring is required new data has shown benefits for the right patient population.

With a unique delivery method, alemtuzumab (Lemtrada) has proven to be an effective treatment option for multiple sclerosis. While careful monitoring is required, new data has shown benefits for the right patient population.

Edward J. Fox, MD, PhD, director of the MS Clinic of Central Texas, discussed the latest research on Lemtrada, which was presented at the 68th Annual Meeting of the American Academy of Neurology in Vancouver.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.